|
|
|
|
|
|
|
|
Press Releases |
|
|
|
Thursday, March 28, 2024 |
|
China Medical System (867.HK) 2023 Annual Results: Despite of the Temporary Financial Performance Pressure, Fresh Catalysts Emerged from Successive Innovation Breakthroughs |
more info >> |
|
Sunday, February 4, 2024 |
|
China Medical System (00867) Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro(R) |
more info >> |
|
Tuesday, January 2, 2024 |
|
CMS(00867) Joins Hands with Pharmaron to Promote the Singapore Manufacturing Plant Acquisition and CDMO Business in SEA |
more info >> |
|
Wednesday, December 13, 2023 |
|
China Medical System: 4 Products Have Been Newly Included or Continued to be Included in the NRDL |
more info >> |
|
Monday, December 4, 2023 |
|
China Medical System: NDA for Additional RA Indication of Methotrexate Injection Accepted in China |
more info >> |
|
Thursday, August 24, 2023 |
|
China Medical System Gained Exclusive License of an Anti-Ischemic Stroke Class 1 Innovative Drug |
more info >> |
|
Monday, July 31, 2023 |
|
China Medical System Once Again Received MSCI-ESG 'AA' Rating, Leading the Industry in ESG Management |
Recently, MSCI (Morgan Stanley Capital International), the world's largest index company, announced the latest Environmental, Social, and Governance (ESG) evaluation report for China Medical System Holdings limited ("CMS" or the "Group"), who achieved an "AA" rating and surpassed 75% of global peers with leading ESG management practices. more info >> |
|
Thursday, June 29, 2023 |
|
China Medical System Included in the First 'Sustainability Yearbook (China)' of S&P Global |
more info >> |
|
Monday, June 12, 2023 |
|
China Medical System: The first 'Diazepam Nasal Spray' Approved for Marketing in China |
more info >> |
|
Tuesday, May 30, 2023 |
|
China Medical System: An Innovative Drug, ILUMETRI 'Tildrakizumab Injection' Approved for Marketing in China |
On May 30, China Medical System Holdings Limited ("CMS" or the "Group") announced that on 26 May 2023, the New Drug Application (NDA) of Tildrakizumab Injection under the brand name of ILUMETRI has been approved by the National Medical Products Administration of China (NMPA). ILUMETRI is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. more info >> |
|
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Gome Retail Streamlines to Focus on Main Business
Mar 29, 2024 15:07 HKT/SGT
|
|
|
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical
Mar 29, 2024 15:51 JST
|
|
|
Gome Fin Tech Announced Annual Results of 2023
Mar 29, 2024 14:36 HKT/SGT
|
|
|
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture
Mar 29, 2024 15:19 JST
|
|
|
Baguio Green's 2023 Adjusted Net Profit increased by 36.7%
Mar 29, 2024 14:15 HKT/SGT
|
|
|
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024
Mar 29, 2024 14:32 JST
|
|
|
Forward Fashion Announced 2023 Annual Results
Mar 29, 2024 13:29 HKT/SGT
|
|
|
Netjoy records new high gross billing hitting RMB8.137 billion in 2023
Mar 29, 2024 12:27 HKT/SGT
|
|
|
Sino Biopharm (1177.HK) Announces 2023 Annual Results
Mar 29, 2024 11:45 HKT/SGT
|
|
|
Wintermar Offshore (WINS:JK) Reports FY2023 Results
Mar 29, 2024 10:15 HKT/SGT
|
|
|
TANAKA Memorial Foundation Announces Recipients of FY2023 Precious Metals Research Grants
Mar 29, 2024 11:00 JST
|
|
|
Fujitsu Selected as CDP Supplier Engagement Leader
Mar 29, 2024 10:28 JST
|
|
|
Mazda Production and Sales Results for February 2024
Mar 29, 2024 10:00 JST
|
|
|
703-Carat L'Heure Bleu Tanzanite Carving Sets New GUINNESS WORLD RECORDS(TM) Title as World's Largest Cut Tanzanite
Mar 29, 2024 06:00 HKT/SGT
|
|
|
Finerca Celebrates Milestone of 10,000 Clients with Launch of Exclusive Master Course in CFD Trading
Mar 29, 2024 05:36 HKT/SGT
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
Copyright © 2024 ACN Newswire - Asia Corporate News Network |
|
Connect With us:
|
|
| |